Scott Ribich

5.4k total citations · 2 hit papers
37 papers, 2.9k citations indexed

About

Scott Ribich is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Scott Ribich has authored 37 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 6 papers in Pathology and Forensic Medicine and 5 papers in Physiology. Recurrent topics in Scott Ribich's work include Cancer-related gene regulation (13 papers), Chromatin Remodeling and Cancer (9 papers) and Epigenetics and DNA Methylation (7 papers). Scott Ribich is often cited by papers focused on Cancer-related gene regulation (13 papers), Chromatin Remodeling and Cancer (9 papers) and Epigenetics and DNA Methylation (7 papers). Scott Ribich collaborates with scholars based in United States, France and Italy. Scott Ribich's co-authors include Antônio C. Bianco, Brian W. Kim, Stephen A. Huang, Ann Marie Zavacki, Warner S. Simonides, Balázs Gereben, Anikó Zeöld, Pamela J. McLean, Bradley T. Hyman and Robert A. Copeland and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Scott Ribich

35 papers receiving 2.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cellular and Molecular Basis of Deiodinase-Regulated Thyroid Hormone Signaling1

2008 643 citations Scott Ribich, Brian W. Kim et al. profile →
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

2018 451 citations Antoîne Italiano, Jean‐Charles Soria et al. The Lancet Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Scott Ribich	1.7k	556	539	291	277	37	2.9k
Mansoor Sarfarazi	2.0k 1.2×	400 0.7×	276 0.5×	275 0.9×	145 0.5×	58	4.7k
Mario Encinas	2.0k 1.2×	402 0.7×	190 0.4×	327 1.1×	247 0.9×	49	3.4k
Antonio Feliciello	2.4k 1.4×	234 0.4×	319 0.6×	351 1.2×	157 0.6×	67	3.5k
Hoa Nguyen	1.6k 0.9×	443 0.8×	262 0.5×	279 1.0×	141 0.5×	31	3.4k
Masatoshi Ichihara	1.5k 0.9×	762 1.4×	246 0.5×	576 2.0×	110 0.4×	82	3.4k
Hsiang–Po Huang	1.8k 1.1×	389 0.7×	739 1.4×	195 0.7×	54 0.2×	63	3.5k
Tomoaki Tanaka	1.6k 0.9×	699 1.3×	653 1.2×	184 0.6×	88 0.3×	133	3.3k
Maria Nesterova	1.5k 0.9×	669 1.2×	632 1.2×	70 0.2×	159 0.6×	71	2.8k
Dominique Joubert	1.4k 0.8×	443 0.8×	345 0.6×	110 0.4×	85 0.3×	68	2.4k
Ilaria T. Cavarretta	839 0.5×	527 0.9×	283 0.5×	205 0.7×	94 0.3×	49	2.2k

Countries citing papers authored by Scott Ribich

Since Specialization

Citations

This map shows the geographic impact of Scott Ribich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Ribich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Ribich more than expected).

Fields of papers citing papers by Scott Ribich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Ribich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Ribich. The network helps show where Scott Ribich may publish in the future.

Co-authorship network of co-authors of Scott Ribich

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Ribich. A scholar is included among the top collaborators of Scott Ribich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Ribich. Scott Ribich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sparling, Brian A., Hyelee Lee, Simina Grigoriu, et al.. (2025). Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom Replacement. ACS Medicinal Chemistry Letters. 16(11). 2309–2319.

House, Nealia C., Maxine Chen, Liang Yuan, et al.. (2025). Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1 -Aberrant Ovarian and Endometrial Tumors. Cancer Research. 85(7). 1297–1309. 6 indexed citations

House, Nealia C., Maxine Chen, Sima Khazaei, et al.. (2025). CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. npj Breast Cancer. 11(1). 135–135. 1 indexed citations

Grassian, Alexandra, Andrew M. Haidle, James Α. Baker, et al.. (2024). BLU-808, a Potent and Selective Small Molecule Inhibitor of Wild-type c-KIT for Mast Cell Disorders. Journal of Allergy and Clinical Immunology. 153(2). AB62–AB62. 4 indexed citations

Buker, Shane M., Zachary A. Gurard‐Levin, Michael D. Scholle, et al.. (2019). A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity. SLAS DISCOVERY. 25(4). 361–371. 36 indexed citations

Boriack‐Sjodin, P. Ann, Scott Ribich, & Robert A. Copeland. (2018). RNA-modifying proteins as anticancer drug targets. Nature Reviews Drug Discovery. 17(6). 435–453. 108 indexed citations

Italiano, Antoîne, Jean‐Charles Soria, Maud Toulmonde, et al.. (2018). Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. The Lancet Oncology. 19(5). 649–659. 451 indexed citations breakdown →

Drew, Allison E., Trupti Lingaraj, Natalie M. Warholic, et al.. (2017). EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL. Molecular Cancer Therapeutics. 16(11). 2586–2597. 52 indexed citations

Chan-Penebre, Elayne, Kelli Armstrong, Allison E. Drew, et al.. (2017). Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models. Molecular Cancer Therapeutics. 16(5). 850–860. 127 indexed citations

10.

Gardner, Eric E., Benjamin H. Lok, Valentina E. Schneeberger, et al.. (2017). Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. Cancer Cell. 31(2). 286–299. 347 indexed citations

11.

Ribich, Scott, et al.. (2017). Drug Discovery and Chemical Biology of Cancer Epigenetics. Cell chemical biology. 24(9). 1120–1147. 35 indexed citations

12.

Kawano, Satoshi, Alexandra Grassian, Masumi Tsuda, et al.. (2016). Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. PLoS ONE. 11(7). e0158888–e0158888. 58 indexed citations

13.

Rioux, Nathalie, Lorna H. Mitchell, Philip R. Tiller, et al.. (2015). Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652. Drug Metabolism and Disposition. 43(7). 936–943. 5 indexed citations

14.

Grassian, Alexandra, Sarah K. Knutson, Kevin W. Kuntz, et al.. (2015). A Medium-Throughput Single Cell CRISPR-Cas9 Assay to Assess Gene Essentiality. Biological Procedures Online. 17(1). 15–15. 5 indexed citations

15.

da‐Silva, Wagner Seixas, Scott Ribich, Rafael Arrojo e Drigo, et al.. (2011). The chemical chaperones tauroursodeoxycholic and 4-phenylbutyric acid accelerate thyroid hormone activation and energy expenditure. FEBS Letters. 585(3). 539–544. 39 indexed citations

16.

Hall, Jessica A., Scott Ribich, Marcelo A. Christoffolete, et al.. (2010). Absence of Thyroid Hormone Activation during Development Underlies a Permanent Defect in Adaptive Thermogenesis. Endocrinology. 151(9). 4573–4582. 85 indexed citations

17.

Kang, Hye Won, Scott Ribich, Brian W. Kim, et al.. (2009). Mice lacking Pctp /StarD2 exhibit increased adaptive thermogenesis and enlarged mitochondria in brown adipose tissue. Journal of Lipid Research. 50(11). 2212–2221. 28 indexed citations

18.

Tasic, Bosiljka, Christoph E. Nabholz, Kristin K. Baldwin, et al.. (2002). Promoter Choice Determines Splice Site Selection in Protocadherin α and γ Pre-mRNA Splicing. Molecular Cell. 10(1). 21–33. 244 indexed citations

19.

McLean, Pamela J., Hibiki Kawamata, Scott Ribich, & Bradley T. Hyman. (2000). Membrane Association and Protein Conformation of α-Synuclein in Intact Neurons. Journal of Biological Chemistry. 275(12). 8812–8816. 211 indexed citations

20.

McLean, Pamela J., Scott Ribich, & Bradley T. Hyman. (2000). Subcellular localization of α-synuclein in primary neuronal cultures: effect of missense mutations. PubMed. 53–63. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact